



DERMATOPATHOLOGY

Meera Mahalingam, MD, PhD, FRCPath

Dermatopathologist

Phone: 1.844.362.9801 | Email: me@meeramahalingam.com

DermPath Diagnostics New England

200 Forest Street, Suite #3119, Marlborough, MA 01752



New England is pleased to welcome Meera Mahalingam, MD, PhD, FRCPath to the dermatopathology team in the north region

Dr. Mahalingam is a board certified pathologist as well as board certified dermatopathologist. She is a prolific writer and prodigious researcher with over 180 original publications, several book chapters and a recently released book (July 2016) entitled *Pearls and Pitfalls in Neoplastic Dermatopathology*.

Dr Mahalingam has served as a Board member of the American Society of Dermatopathology (ASDP) since 2003 in key leadership positions. She is an invited speaker at both national as well as international dermatology, pathology and dermatopathology meetings and serves on multiple editorial boards (*Journal of Cutaneous Pathology, Modern Pathology, Human Pathology and Advances in Anatomic Pathology*). In 2014, she was invited by the American Board of Pathology to serve as a member of the Dermatopathology Test Advisory Committee, a position she continues to hold to this date.

Board Certifications

Anatomic and Clinical Pathology
Dermatopathology

Residencies

Anatomic and Clinical Pathology
Boston Medical Center
Boston, MA

Medical School

Darbhanga Medical College,
Mithila University
Darbhanga, India

Fellowship

Dermatopathology
Boston University
School of Medicine
Boston, MA

Anatomic and Clinical Pathology
Arrowe Park/Royal Liverpool
Hospital, Ashford Hospital,
Middlesex, King's College Hospital
London, UK

Select Publications

Frydenlund N, Leone D, Mitchell B, Yang S, Deng A, Hoang MP, **Mahalingam M**. Neurotrophin receptors and perineural invasion in desmoplastic melanoma. *J Am Acad Derm* 2015;72: 851

Filitis D, **Mahalingam M**. Adverse cutaneous reactions to BRAF-inhibitors- An analysis with emphasis on effects associated with each inhibitor and therapeutic time interval to onset. *Am J Clin Dermatol* 2013;14:461

Feller K, Yang S, **Mahalingam M**. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. *Mod Pathol*. 2013;26:414

Mahalingam M, Nguyen LP, Richards JE, Muzikansky A, Hoang MP. The Diagnostic Utility of Immunohistochemistry in Distinguishing Primary Skin Adnexal Carcinomas from Metastatic Adenocarcinoma to Skin: an Immunohistochemical Reappraisal Using Cytokeratin 15, Nestin, p63, D2-40, and Calretinin. *Mod Pathol*. 2010;23:713

Abbas O, **Mahalingam M**. Cutaneous Sebaceous neoplasms as markers of Muir-Torre syndrome- A diagnostic algorithm. *J Cut Pathol*. 2009; 36:613

Mahalingam M. Quality assurance and continuing medical education in dermatopathology – the ASDP way. (invited Editorial) *J Cutan Pathol*. 2008; 35:516

DermPathDiagnostics.com

DermPath Diagnostics, any associated logos, and all associated DermPath Diagnostics registered or unregistered trademarks are the property of DermPath Diagnostics. All third-party marks-® and ™-are the property of their respective owners. ©2017 DermPath Diagnostics Incorporated. All rights reserved. 6/2017